Taysha Gene Therapies, Inc.

On December 13, 2024, the Company filed a shelf registration statement on Form S-3 following the expiration of its prior registration statement, in relation to the registration of common stock, preferred stock, debt securities, warrants and units or any combination thereof up to a total aggregate offering price of $ 300.0 million, including up to $ 100.0 million shares of common stock that could be offered and sold pursuant to the Sales Agreement.

SEC original ↗Taysha Gene Therapies, Inc. — 10-Q Quarterly report10-QAug 11, 2026

The Company expects to finance its future cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances or licensing arrangements.

SEC original ↗Taysha Gene Therapies, Inc. — 10-Q Quarterly report10-QAug 11, 2026

Note 7 Term Loans 2025 Loan with Trinity Capital On August 7, 2025 (the Trinity Refinance Date ), the Company entered into a Loan and Security Agreement (the 2025 Trinity Term Loan Agreement ), by and among the Company, the lenders party thereto from time to time (the 2025 Trinity Lenders ) and Trinity Capital Inc.

SEC original ↗Taysha Gene Therapies, Inc. — 10-Q Quarterly report10-QAug 11, 2026

The existing 2023 Trinity Term Loan Agreement was terminated and the existing 2023 Trinity Term Loans were repaid concurrently with entry into the 2025 Trinity Term Loan Agreement and the draw of Tranche A.

SEC original ↗Taysha Gene Therapies, Inc. — 10-Q Quarterly report10-QAug 11, 2026

The 2025 Trinity Term Loans are interest only from the Trinity Refinance Date through 48 months from the Trinity Refinance Date, which may be extended to 60 months from the Trinity Refinance Date upon the satisfaction of certain milestones set forth in the 2025 Trinity Term Loan Agreement, after which the Company is required to pay equal monthly installments of principal through August 1, 2030 (the New Maturity Date ).

SEC original ↗Taysha Gene Therapies, Inc. — 10-Q Quarterly report10-QAug 11, 2026

As of June 30, 2026, $ 50.0 million was outstanding on the 2025 Trinity Term Loans, recorded as Term Loan, net on the condensed consolidated balance sheet.

SEC original ↗Taysha Gene Therapies, Inc. — 10-Q Quarterly report10-QAug 11, 2026

(Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today reported financial results for the second quarter ended June 30, 2025, and provided a corporate update.

SEC original ↗Taysha Gene Therapies, Inc. — Earnings release (8-K exhibit)EX-99Aug 12, 2025

The $5.0 million increase was driven by BLA-enabling process performance qualification (PPQ) manufacturing initiatives, REVEAL clinical trial activities and higher compensation expenses as a result of increased headcount during the three months ended June 30, 2025.

SEC original ↗Taysha Gene Therapies, Inc. — Earnings release (8-K exhibit)EX-99Aug 12, 2025

About Taysha Gene Therapies Taysha Gene Therapies (Nasdaq: TSHA) is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system.

SEC original ↗Taysha Gene Therapies, Inc. — Earnings release (8-K exhibit)EX-99Aug 12, 2025

With a singular focus on developing transformative medicines, Taysha aims to address severe unmet medical needs and dramatically improve the lives of patients and their caregivers.

SEC original ↗Taysha Gene Therapies, Inc. — Earnings release (8-K exhibit)EX-99Aug 12, 2025

Taysha is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for severe monogenic diseases of the central nervous system.

SEC original ↗Taysha Gene Therapies, Inc. — 10-Q Quarterly report10-QAug 11, 2026

Forward-looking statements are based on management s current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements.

SEC original ↗Taysha Gene Therapies, Inc. — Earnings release (8-K exhibit)EX-99Aug 12, 2025

Legal Proceedings 46 Item 1A.

SEC original ↗Taysha Gene Therapies, Inc. — 10-Q Quarterly report10-QAug 11, 2026

If the Company is unable to obtain funding, the Company would be forced to delay, reduce or eliminate some or all of its research and development programs, preclinical and clinical testing or commercialization efforts, which could adversely affect its business prospects.

SEC original ↗Taysha Gene Therapies, Inc. — 10-Q Quarterly report10-QAug 11, 2026